Your browser doesn't support javascript.
loading
Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Burgener, Justin M; Zou, Jinfeng; Zhao, Zhen; Zheng, Yangqiao; Shen, Shu Yi; Huang, Shao Hui; Keshavarzi, Sareh; Xu, Wei; Liu, Fei-Fei; Liu, Geoffrey; Waldron, John N; Weinreb, Ilan; Spreafico, Anna; Siu, Lillian L; de Almeida, John R; Goldstein, David P; Hoffman, Michael M; De Carvalho, Daniel D; Bratman, Scott V.
Affiliation
  • Burgener JM; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Zou J; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Zhao Z; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Zheng Y; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Shen SY; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Huang SH; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Keshavarzi S; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Xu W; Deparment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Liu FF; Deparment of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Liu G; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Waldron JN; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Weinreb I; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Spreafico A; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Siu LL; Deparment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • de Almeida JR; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Goldstein DP; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Hoffman MM; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • De Carvalho DD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Bratman SV; Deparment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Clin Cancer Res ; 27(15): 4230-4244, 2021 08 01.
Article in En | MEDLINE | ID: mdl-34158359
ABSTRACT

PURPOSE:

Circulating tumor DNA (ctDNA) enables personalized treatment strategies in oncology by providing a noninvasive source of clinical biomarkers. In patients with low ctDNA abundance, tumor-naïve methods are needed to facilitate clinical implementation. Here, using locoregionally confined head and neck squamous cell carcinoma (HNSCC) as an example, we demonstrate tumor-naïve detection of ctDNA by simultaneous profiling of mutations and methylation. EXPERIMENTAL

DESIGN:

We conducted CAncer Personalized Profiling by deep Sequencing (CAPP-seq) and cell-free Methylated DNA ImmunoPrecipitation and high-throughput sequencing (cfMeDIP-seq) for detection of ctDNA-derived somatic mutations and aberrant methylation, respectively. We analyzed 77 plasma samples from 30 patients with stage I-IVA human papillomavirus-negative HNSCC as well as plasma samples from 20 risk-matched healthy controls. In addition, we analyzed leukocytes from patients and controls.

RESULTS:

CAPP-seq identified mutations in 20 of 30 patients at frequencies similar to that of The Tumor Genome Atlas (TCGA). Differential methylation analysis of cfMeDIP-seq profiles identified 941 ctDNA-derived hypermethylated regions enriched for CpG islands and HNSCC-specific methylation patterns. Both methods demonstrated an association between ctDNA abundance and shorter fragment lengths. In addition, mutation- and methylation-based ctDNA abundance was highly correlated (r > 0.85). Patients with detectable pretreatment ctDNA by both methods demonstrated significantly worse overall survival (HR = 7.5; P = 0.025) independent of clinical stage, with lack of ctDNA clearance post-treatment strongly correlating with recurrence. We further leveraged cfMeDIP-seq profiles to validate a prognostic signature identified from TCGA samples.

CONCLUSIONS:

Tumor-naïve detection of ctDNA by multimodal profiling may facilitate biomarker discovery and clinical use in low ctDNA abundance applications.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Circulating Tumor DNA / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Circulating Tumor DNA / Squamous Cell Carcinoma of Head and Neck / Head and Neck Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Canada